DK2234617T3 - Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere - Google Patents

Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere Download PDF

Info

Publication number: DK2234617T3
Authority: DK; Denmark
Prior art keywords: paliperidones; injective; term; long; dosage schedule
Prior art date: 2007-12-19

Application number

DK08863534.7T

Other languages

English (en)

Inventor

An Margriet Cornelia Vermeulen

Alfons Jeanne Wouters

Srihari Gopal

Vivek Kusamaker

Peter H Lewyn-Briscoe

Mahesh Samtani

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-19

Filing date

2008-12-17

Publication date

2021-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40428256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2234617(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-17 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2021-05-25 Application granted granted Critical

2021-05-25 Publication of DK2234617T3 publication Critical patent/DK2234617T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
- H01L31/109—

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Addiction (AREA)
Dermatology (AREA)
Condensed Matter Physics & Semiconductors (AREA)
Power Engineering (AREA)
Microelectronics & Electronic Packaging (AREA)
Computer Hardware Design (AREA)
Manufacturing & Machinery (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK08863534.7T 2007-12-19 2008-12-17 Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere DK2234617T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1491807P	2007-12-19	2007-12-19
US12027608P	2008-12-05	2008-12-05
PCT/EP2008/067738 WO2009080651A1 (en)	2007-12-19	2008-12-17	Dosing regimen associated with long acting injectable paliperidone esters

Publications (1)

Publication Number	Publication Date
DK2234617T3 true DK2234617T3 (da)	2021-05-25

Family

ID=40428256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08863534.7T DK2234617T3 (da)	2007-12-19	2008-12-17	Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere

Country Status (27)

Country	Link
US (3)	US9439906B2 (da)
EP (2)	EP3909585A1 (da)
JP (1)	JP5825786B2 (da)
KR (3)	KR102163196B1 (da)
CN (2)	CN105560176A (da)
AU (2)	AU2008340101B2 (da)
BR (1)	BRPI0821408A2 (da)
CO (1)	CO6300949A2 (da)
CY (1)	CY1124103T1 (da)
DK (1)	DK2234617T3 (da)
EA (1)	EA020697B1 (da)
EC (1)	ECSP10010289A (da)
ES (1)	ES2868353T3 (da)
GT (1)	GT201000182A (da)
HK (1)	HK1223850A1 (da)
HR (1)	HRP20210669T1 (da)
HU (1)	HUE053904T2 (da)
IL (2)	IL206448A (da)
LT (1)	LT2234617T (da)
MY (1)	MY204500A (da)
NI (1)	NI201000105A (da)
NZ (1)	NZ586221A (da)
PL (1)	PL2234617T3 (da)
PT (1)	PT2234617T (da)
RS (1)	RS61765B1 (da)
SI (1)	SI2234617T1 (da)
WO (1)	WO2009080651A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP5825786B2 (ja) *	2007-12-19	2015-12-02	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	長時間作用型注入可能パリペリドンエステルに関連する投薬計画
US8758780B2 (en) *	2009-10-06	2014-06-24	Ascendis Pharma As	Subcutaneous paliperidone composition
US20130053405A1 (en) *	2009-10-06	2013-02-28	Ulrich Hersel	Carrier linked paliperidone prodrugs
KR20120116401A (ko) *	2009-10-30	2012-10-22	얀센 파마슈티카 엔.브이.	장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
US9271939B2 (en)	2010-03-15	2016-03-01	Inventia Healthcare Private Limited	Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
US9522980B2 (en)	2010-05-06	2016-12-20	Johnson & Johnson Vision Care, Inc.	Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same
TWI577377B (zh) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
RS55434B1 (sr) *	2011-03-18	2017-04-28	Alkermes Pharma Ireland Ltd	Injektabilne farmaceutske kompozicije koje sadrže antipsihotik koji je nerastvorljiv u vodi, sorbitan laurat i polisorbat 20
US9170349B2 (en)	2011-05-04	2015-10-27	Johnson & Johnson Vision Care, Inc.	Medical devices having homogeneous charge density and methods for making same
SI2529757T1 (sl)	2011-05-31	2014-05-30	Laboratorios Farmaceuticos Rovi, S.A.	Formulacija paliperidon implantata
PT2529756T (pt)	2011-05-31	2021-07-28	Farm Rovi Lab Sa	Formulação de implante de risperidona e/ou paliperidona
CN102274164B (zh) *	2011-08-22	2014-07-02	长春健欣生物医药科技开发有限公司	帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
CN103301461B (zh) *	2012-03-08	2018-09-07	江苏豪森药业集团有限公司	一种长效注射制剂及其制备方法和用途
JP6471089B2 (ja)	2012-03-19	2019-02-13	アルカームスファーマアイルランドリミテッド	脂肪酸エステルを含む医薬組成物
ES2950418T3 (es)	2012-03-19	2023-10-09	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden alcohol bencílico
WO2013142202A1 (en)	2012-03-19	2013-09-26	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising glycerol esters
US9244196B2 (en)	2012-05-25	2016-01-26	Johnson & Johnson Vision Care, Inc.	Polymers and nanogel materials and methods for making and using the same
US10073192B2 (en)	2012-05-25	2018-09-11	Johnson & Johnson Vision Care, Inc.	Polymers and nanogel materials and methods for making and using the same
ES2792149T3 (es)	2012-09-19	2020-11-10	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
CN106132415A (zh)	2014-03-20	2016-11-16	奥克梅斯制药爱尔兰有限公司	具有增加的注射速度的阿立哌唑制剂
PT3185867T (pt)	2014-08-25	2021-04-12	Alkermes Pharma Ireland Ltd	Processo de cristalização de derivados de aripiprazol em formulações de libertação prolongada para tratamento de esquizofrenia
US9844551B2 (en)	2015-01-14	2017-12-19	Children's Hospital Medical Center	Compositions and methods for treatment of fragile X syndrome
CN107249586A (zh)	2015-02-17	2017-10-13	万达制药公司	用于治疗精神分裂症的伊潘立酮
WO2016157061A1 (en)	2015-03-31	2016-10-06	Wockhardt Limited	Aseptic wet milling process for paliperidone palmitate
EP4349323A3 (en) *	2015-04-07	2024-06-12	JANSSEN Pharmaceutica NV	Dosing regimen for missed doses for long-acting injectable paliperidone esters
WO2018098115A1 (en) *	2016-11-23	2018-05-31	Children's Hospital Medical Center	Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
WO2019084501A1 (en) *	2017-10-27	2019-05-02	Shandong Luye Pharmaceutical Co., Ltd.	DOSAGE PLAN OF INJECTABLE SUSPENSION WITH EXTENDED RELEASE OF PALIPERIDONE PALMITATE
CA3092335A1 (en)	2018-03-05	2019-09-12	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
CN110279659A (zh) *	2019-07-08	2019-09-27	华裕(无锡)制药有限公司	棕榈酸帕利哌酮制剂及其制备方法
GR1009869B (el) *	2019-07-12	2020-11-12	Φαρματεν Α.Β.Ε.Ε.	Ενεσιμο παρατεταμενης αποδεσμευσης φαρμακευτικο σκευασμα που περιλαμβανει παλμιτικη παλιπεριδονη και μεθοδος παρασκευης αυτου
WO2022006336A1 (en) *	2020-07-01	2022-01-06	Jubilant Pharma Holdings Inc.	Long-acting injection dosage form of beta 3 adrenoreceptor agonists
PL4025188T3 (pl)	2020-11-30	2024-06-17	Janssen Pharmaceutica Nv	Schematy dawkowania związane z preparatami paliperydonu o przedłużonym uwalnianiu do wstrzykiwania
MX2023006370A (es)	2020-11-30	2023-08-07	Janssen Pharmaceutica Nv	Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
HRP20240800T1 (hr)	2020-11-30	2024-09-27	Janssen Pharmaceutica Nv	Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
WO2022112367A1 (en)	2020-11-30	2022-06-02	Janssen Pharmaceutica Nv	Methods for ensuring resuspension of paliperidone palmitate formulations
RU2756614C1 (ru) *	2021-04-07	2021-10-04	Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ)	Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии
KR20240049580A (ko)	2021-08-20	2024-04-16	얀센 파마슈티카 엔브이	서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1491807A (en)	1922-06-20	1924-04-29	John P Mclinn	Traveling bag
US1491809A (en)	1923-02-17	1924-04-29	Us Fireworks Mfg Company Inc	Toy
US4804663A (en) *	1985-03-27	1989-02-14	Janssen Pharmaceutica N.V.	3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) *	1988-11-07	1992-10-27	Janssen Pharmaceutica N.V.	3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en)	1988-11-07	1993-10-19	Janssen Pharmaceutica N.V.	3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) *	1993-04-28	1999-12-11	Janssen Pharmaceutica Nv	Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) *	1994-07-11	1995-09-26	Janssen Pharmaceutica N.V.	Risperidone oral formulation
TW487572B (en) *	1996-05-20	2002-05-21	Janssen Pharmaceutica Nv	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AU5489299A (en) *	1998-08-18	2000-03-14	Sepracor, Inc.	Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
KR100338776B1 (ko)	2000-07-11	2002-05-31	윤종용	멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
WO2004010981A1 (en) *	2002-07-29	2004-02-05	Alza Corporation	Methods and dosage forms for controlled delivery of paliperidone
AU2003265511A1 (en)	2002-08-21	2004-03-11	Pharmacia Corporation	Injectable pharmaceutical suspension in a two-chamber vial
US20060079846A1 (en)	2004-10-08	2006-04-13	Alton Williams	Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such
WO2006114384A1 (en)	2005-04-25	2006-11-02	Janssen Pharmaceutica N.V.	Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US20070197591A1 (en) *	2005-12-12	2007-08-23	Sandra Boom	Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
US20070232624A1 (en) *	2006-04-03	2007-10-04	Palumbo Joseph M	Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
JP2009524685A (ja)	2006-08-14	2009-07-02	テバファーマシューティカルインダストリーズリミティド	９−ヒドロキシ−リスペリドン（パリペリドン）の結晶型
US20090087487A1 (en)	2007-08-21	2009-04-02	Michael Fox	Paliperidone sustained release formulation
KR20100091959A (ko)	2007-10-09	2010-08-19	시플라 리미티드	팔리페리돈 및 그의 약학적으로 허용가능한 염의 제조방법 및 상기 제조방법에 사용되는 중간체
JP5825786B2 (ja)	2007-12-19	2015-12-02	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	長時間作用型注入可能パリペリドンエステルに関連する投薬計画
KR20120116401A (ko) *	2009-10-30	2012-10-22	얀센 파마슈티카 엔.브이.	장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
US11114549B2 (en)	2017-11-29	2021-09-07	Taiwan Semiconductor Manufacturing Co., Ltd.	Semiconductor structure cutting process and structures formed thereby
US11450758B2 (en)	2020-06-12	2022-09-20	Taiwan Semiconductor Manufacturing Co., Ltd.	Gate structure of semiconductor device and method of forming same

2008
- 2008-12-17 JP JP2010538703A patent/JP5825786B2/ja active Active
- 2008-12-17 PL PL08863534T patent/PL2234617T3/pl unknown
- 2008-12-17 WO PCT/EP2008/067738 patent/WO2009080651A1/en active Application Filing
- 2008-12-17 DK DK08863534.7T patent/DK2234617T3/da active
- 2008-12-17 LT LTEP08863534.7T patent/LT2234617T/lt unknown
- 2008-12-17 AU AU2008340101A patent/AU2008340101B2/en active Active
- 2008-12-17 MY MYPI2010002906A patent/MY204500A/en unknown
- 2008-12-17 NZ NZ586221A patent/NZ586221A/xx unknown
- 2008-12-17 KR KR1020177003860A patent/KR102163196B1/ko active IP Right Grant
- 2008-12-17 KR KR1020107015670A patent/KR20100099292A/ko active Search and Examination
- 2008-12-17 BR BRPI0821408-5A patent/BRPI0821408A2/pt not_active Application Discontinuation
- 2008-12-17 RS RS20210495A patent/RS61765B1/sr unknown
- 2008-12-17 CN CN201610011987.6A patent/CN105560176A/zh active Pending
- 2008-12-17 ES ES08863534T patent/ES2868353T3/es active Active
- 2008-12-17 EP EP21164550.2A patent/EP3909585A1/en active Pending
- 2008-12-17 US US12/337,144 patent/US9439906B2/en active Active
- 2008-12-17 KR KR1020197012533A patent/KR102318070B1/ko active IP Right Grant
- 2008-12-17 HU HUE08863534A patent/HUE053904T2/hu unknown
- 2008-12-17 EA EA201070757A patent/EA020697B1/ru not_active IP Right Cessation
- 2008-12-17 CN CN2008801261088A patent/CN101932327A/zh active Pending
- 2008-12-17 EP EP08863534.7A patent/EP2234617B2/en active Active
- 2008-12-17 PT PT88635347T patent/PT2234617T/pt unknown
- 2008-12-17 SI SI200832163T patent/SI2234617T1/sl unknown
2010
- 2010-06-17 IL IL206448A patent/IL206448A/en unknown
- 2010-06-18 GT GT201000182A patent/GT201000182A/es unknown
- 2010-06-18 EC EC2010010289A patent/ECSP10010289A/es unknown
- 2010-06-18 NI NI201000105A patent/NI201000105A/es unknown
- 2010-06-23 CO CO10075713A patent/CO6300949A2/es not_active Application Discontinuation
2015
- 2015-02-18 AU AU2015200801A patent/AU2015200801B2/en active Active
2016
- 2016-08-25 US US15/247,149 patent/US20170128451A1/en not_active Abandoned
- 2016-10-26 HK HK16112292.2A patent/HK1223850A1/zh unknown
2017
- 2017-07-13 IL IL253468A patent/IL253468A0/en unknown
2018
- 2018-01-25 US US15/880,160 patent/US20180147210A1/en not_active Abandoned
2021
- 2021-04-27 HR HRP20210669TT patent/HRP20210669T1/hr unknown
- 2021-05-12 CY CY20211100404T patent/CY1124103T1/el unknown

Also Published As

Publication number	Publication date
HUE053904T2 (hu)	2021-07-28
CN105560176A (zh)	2016-05-11
US9439906B2 (en)	2016-09-13
JP5825786B2 (ja)	2015-12-02
BRPI0821408A2 (pt)	2015-06-16
WO2009080651A1 (en)	2009-07-02
ES2868353T3 (es)	2021-10-21
ECSP10010289A (es)	2010-07-30
IL206448A0 (en)	2010-12-30
US20170128451A1 (en)	2017-05-11
LT2234617T (lt)	2021-05-25
JP2011506555A (ja)	2011-03-03
KR20190049933A (ko)	2019-05-09
NI201000105A (es)	2011-03-17
KR20100099292A (ko)	2010-09-10
KR20170018489A (ko)	2017-02-17
MY204500A (en)	2024-08-30
HRP20210669T1 (hr)	2021-10-29
SI2234617T1 (sl)	2021-07-30
CN101932327A (zh)	2010-12-29
CO6300949A2 (es)	2011-07-21
AU2008340101B2 (en)	2015-02-19
IL206448A (en)	2017-12-31
NZ586221A (en)	2012-08-31
CY1124103T1 (el)	2022-05-27
IL253468A0 (en)	2017-09-28
GT201000182A (es)	2012-03-26
EP3909585A1 (en)	2021-11-17
EP2234617B2 (en)	2024-11-06
AU2015200801B2 (en)	2016-12-15
KR102318070B1 (ko)	2021-10-27
HK1223850A1 (zh)	2017-08-11
US20090163519A1 (en)	2009-06-25
PL2234617T3 (pl)	2021-11-08
AU2015200801A1 (en)	2015-03-12
EA020697B1 (ru)	2015-01-30
EA201070757A1 (ru)	2011-02-28
US20180147210A1 (en)	2018-05-31
EP2234617A1 (en)	2010-10-06
EP2234617B1 (en)	2021-03-31
PT2234617T (pt)	2021-05-18
KR102163196B1 (ko)	2020-10-12
RS61765B1 (sr)	2021-05-31
AU2008340101A1 (en)	2009-07-02

Publication	Publication Date	Title
DK2234617T3 (da)	2021-05-25	Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
FIC20220047I1 (fi)	2022-12-12	Avalglucosidase alfa
DK2479264T3 (da)	2014-08-04	Glucoamylasevarianter med ændrede egenskaber
DK2099453T3 (da)	2017-11-06	Kombinationsterapi med substituerede oxazolidinoner
DK2527713T3 (da)	2014-01-27	Blender med stigningsgrad
BRPI0720699A2 (pt)	2014-02-18	Programas ligados
DK2029458T3 (da)	2011-05-02	Kapsel med mindsket dryppen
DK2479265T3 (da)	2014-09-08	Glucoamylasevarianter med ændrede egenskaber
DK2139987T3 (da)	2013-09-02	Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
DK2245130T3 (da)	2021-01-18	Ts23 -alpha-amylasevarianter med ændrede egenskaber
DK2106215T3 (da)	2020-09-28	Brød med forhøjet arabinoxylo-oligosaccharid-indhold
DK2182863T3 (da)	2012-07-16	Åbningsdilatator
BRPI1006175A2 (pt)	2017-03-21	composição agroquímica estabilizada
DK2280734T3 (da)	2014-05-26	Faktor-ix-konjugater med forlængede halveringstider
BRPI1013030A2 (pt)	2016-04-05	"aquecedores"
DK2125048T3 (da)	2014-10-13	Præparat
DK2131818T3 (da)	2014-05-26	Ny doseringsform
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
DK1927646T3 (da)	2012-10-29	Odoriseringsmiddel med forbedret stabilitet
DK2236023T3 (da)	2013-06-17	Stald med gulvelement
DK2152881T3 (da)	2014-07-14	RumC-peptider med antimikrobiel aktivitet
DK2257292T3 (da)	2014-09-29	Kombinationsterapi med Zn/trimethoprim
BRPI0807654A2 (pt)	2014-06-03	Terapia com vacinas para a neovascularização de coroide
DK1970496T3 (da)	2013-10-07	Doseringsarrangement
ES1065510Y (es)	2007-12-01	Chimenea